{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"491.6","spread":"491.6","value":"429.6"},{"groupId":"OG001","lowerLimit":"356.2","spread":"356.2","value":"260.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"325"}],"units":"Participants"}],"description":"Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"},{"description":"Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.","id":"OG001","title":"Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Safety analysis population included all randomized participants who received at least 1 dose of study treatment. Data is reported for pMMR participants. Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 77 months","title":"Time to Treatment Failure Due to Toxicity in pMMR Participants","type":"SECONDARY","unitOfMeasure":"Months"}